Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Revenue (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Revenue for 16 consecutive years, with $264.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 10461.32% year-over-year to $264.0 million, compared with a TTM value of $1.1 billion through Dec 2025, up 43539.24%, and an annual FY2025 reading of $829.4 million, up 23258.15% over the prior year.
  • Revenue was $264.0 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $256.5 million in the prior quarter.
  • Across five years, Revenue topped out at $542.7 million in Q1 2025 and bottomed at $2.5 million in Q4 2024.
  • Average Revenue over 5 years is $99.9 million, with a median of $32.8 million recorded in 2021.
  • The sharpest move saw Revenue crashed 94.32% in 2023, then surged 10461.32% in 2025.
  • Year by year, Revenue stood at $27.4 million in 2021, then skyrocketed by 127.95% to $62.5 million in 2022, then plummeted by 94.32% to $3.6 million in 2023, then dropped by 29.6% to $2.5 million in 2024, then soared by 10461.32% to $264.0 million in 2025.
  • Business Quant data shows Revenue for ARWR at $264.0 million in Q4 2025, $256.5 million in Q3 2025, and $27.8 million in Q2 2025.